FT819 in Moderate to Severe Active Systemic Lupus Erythematosus - Trial NCT06308978
Access comprehensive clinical trial information for NCT06308978 through Pure Global AI's free database. This Phase 1 trial is sponsored by Fate Therapeutics and is currently Recruiting. The study focuses on Systemic Lupus Erythematosus. Target enrollment is 32 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Fate Therapeutics
Timeline & Enrollment
Phase 1
Feb 24, 2024
Sep 30, 2042
Primary Outcome
Number of participants with treatment-emergent adverse events (TEAEs),Number of participants with serious TEAEs,Number of participants with adverse events of special interest (AESI),Number of participants with TEAEs by severity,Number of participants with dose-limiting toxicities (DLTs),Recommend Phase 2 dose (RP2D) of FT819
Summary
This is a phase 1 study designed to evaluate the safety, pharmacokinetics (PK), and
 anti-B-cell activity of FT819 following conditioning chemotherapy in participants with
 moderate to severe active systemic lupus erythematosus (SLE). The study will consist of a
 dose-escalation stage, followed by an expansion stage to further evaluate the safety and
 activity of FT819.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06308978
Non-Device Trial